The South America sepsis diagnostics market is expected to grow from US$ 38.66 million in 2021 to US$ 69.59 million by 2028; it is estimated to grow at a CAGR of 8.8% from 2021 to 2028.
Infection is the root cause of sepsis. Sepsis mainly occurs in immunocompromised people, such as those taking chemotherapy, having a splenectomy, and suffering from AIDS and chronic illnesses like diabetes. Among several types of infections, nosocomial infections are the primary cause of morbidity and mortality among hospitalized patients. Thus, the rising bloodstream infections will increase the adoption of sepsis diagnostic products. Sepsis has a high mortality and morbidity rate. According to an article published by the National Center for Biotechnology Information (NCBI) in February 2019, sepsis mortality rate was ~25–30%. Additionally, in September 2020, the World Health Organization (WHO) estimated that each year almost 50% of cases of sepsis occur among children, resulting in 2.9 million deaths. Most deaths can be prevented through early diagnosis and appropriate clinical management. These deaths are often a consequence of diarrheal diseases or lower respiratory infections. Thus, the high incidence rate of sepsis is expected to boost the demand for sepsis diagnostic products, thereby supporting the sepsis diagnostics market growth during the forecast period.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South America sepsis diagnostics market. The South America sepsis diagnostics market is expected to grow at a good CAGR during the forecast period.
South America Sepsis Diagnostics Market Revenue and Forecast to 2028 (US$ Million)
South America Sepsis Diagnostics Market Segmentation
The South America sepsis diagnostics market is segmented based on product, technology, method, test type, pathogen, end user, and country. Based on product, the market is divided into instruments, reagents and assays, blood culture media, and software. The blood culture media segment dominated the South America sepsis diagnostics market in 2021. In terms of technology, the market is categorized into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment dominated the South America sepsis diagnostics market in 2021. Based on method, the South America sepsis diagnostics market is categorized into automated diagnostics and conventional diagnostics. The conventional diagnostics segment dominated the market in 2021. Based on test type, the South America sepsis diagnostics market is categorized into point-of-care tests and laboratory tests. The laboratory tests segment dominated the market in 2021. In terms of pathogen, the South America sepsis diagnostics market is categorized into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment dominated the market in 2021. Based on end user, the South America sepsis diagnostics market is categorized into hospitals, pathology and reference laboratories, and others. The hospitals segment dominated the market in 2021. Based on country, the South America sepsis diagnostics market is segmented into Brazil, Argentina, and the Rest of South America. Brazil dominated the South America sepsis diagnostics market in 2021.
Key players operating in the South America sepsis diagnostics market include Abbott; F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; BD; Danaher (Beckman Coulter); Luminex Corporation; THERMO FISHER SCIENTIFIC INC.; bioMerieux SA; and T2 Biosystems, Inc. by Altair.